Dr. Chris Pak has been in the Biotechnology field for over two decades. He is a co-founder, Chairman and CEO of Molecular Targeting Technologies, Inc. (MTTI), a U.S. based Biotechnology Company focused on developing novel medical imaging products as well as potent vaccines. Specifically, MTTI is developing agents for molecular imaging of cancer and cardiovascular diseases for non-invasive disease diagnoses and therapies. Dr. Pak has made extensive contributions in both scientific research as well as entrepreneurship. He was formerly associated with Centocor, a top-tier biopharmaceutical company, where he focused on the research and development of novel products for unmet medical needs. During his tenure at Centocor, he filed 12 IND's for use in cardiovascular diseases and cancer. In addition to his important roles in a number of medical and entrepreneurial associations, he serves as on the board of Minority Group of Ben Franklin Technology Partners, the Pennsylvania Academy of Science, and Comprehensive Drug Enterprises Limited, and honorary advisor of the National University of Singapore Biovalley Program. Dr. Pak currently holds 10 patents in diagnostic imaging and therapy and has published over 50 articles relating to the use of antibodies for cancer and cardiovascular disease. His notable contributions to both science and entrepreneurship have been awarded by receiving the Distinguished Visiting Alumni Award from the State University of New York at Plattsburgh, by the State University of N.Y. for the Honor Roll of Alumni, and by the Ben Franklin Technology Partners for the Emerging Business Award.